hypericin has been researched along with Skin Neoplasms in 18 studies
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma." | 9.14 | A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. ( Cabana, B; Duvic, M; Rook, AH; Tobia, A; Vonderheid, EC; Wood, GS, 2010) |
| "In a syngeneic subcutaneous glioma mouse model we investigated the time dependent hypericin (HYP) uptake in malignant tumor tissue by microendoscopically fluorescence measurements." | 7.79 | Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model. ( Ehrhardt, A; Feigl, GC; Göbel, W; Mayer, D; Naumann, U; Noell, S; Ritz, R; Serifi, D, 2013) |
| "Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects." | 7.11 | Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. ( Akilov, O; Appel, J; Bhatia, N; Boh, E; Bohjanen, K; Carter, J; Dawes, K; DeSimone, JA; Donini, O; Duvic, M; Elston, D; Geskin, L; Girardi, M; Guitart, J; Haulenbeek, A; Huen, A; Kim, EJ; Kim, YH; Korman, NJ; Kuzel, TM; Lain, E; Lee, ST; Mangold, AR; Musiek, A; Nikbakht, N; Olsen, E; Pacheco, T; Pariser, D; Piette, W; Poligone, B; Pullion, C; Querfeld, C; Rook, AH; Rumage, A; Schaber, CJ; Seminario-Vidal, L; Shinohara, M; Straube, R; Wong, HK; Wood, GS; Zeitouni, N; Zwerner, JP, 2022) |
| "Hypericin was taken up by all melanoma cells and partially co-localized to the endoplasmic reticulum, mitochondria, lysosomes and melanosomes, but not the nucleus." | 5.40 | St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. ( Davids, LM; Kleemann, B; Lang, D; Loos, B; Scriba, TJ, 2014) |
| "Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma." | 5.14 | A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. ( Cabana, B; Duvic, M; Rook, AH; Tobia, A; Vonderheid, EC; Wood, GS, 2010) |
| "In a syngeneic subcutaneous glioma mouse model we investigated the time dependent hypericin (HYP) uptake in malignant tumor tissue by microendoscopically fluorescence measurements." | 3.79 | Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model. ( Ehrhardt, A; Feigl, GC; Göbel, W; Mayer, D; Naumann, U; Noell, S; Ritz, R; Serifi, D, 2013) |
| " In the present study, the efficacy of topical hypericin-PDT was evaluated using a mouse model for actinic keratosis." | 3.77 | Photodynamic therapy using topically applied hypericin: comparative effect with methyl-aminolevulinic acid on UV induced skin tumours. ( Boiy, A; de Witte, PA; Roelandts, R, 2011) |
| "We describe the first local use of hypericin as photosensitizer for photodynamic therapy in a patient with recurrent malignant mesothelioma." | 3.69 | Hypericin in phototherapy. ( Alth, G; Ebermann, R; Jindra, RH; Koderhold, G; Koren, H; Kreitner, M; Kubin, A; Schenk, GM, 1996) |
| "Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects." | 3.11 | Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. ( Akilov, O; Appel, J; Bhatia, N; Boh, E; Bohjanen, K; Carter, J; Dawes, K; DeSimone, JA; Donini, O; Duvic, M; Elston, D; Geskin, L; Girardi, M; Guitart, J; Haulenbeek, A; Huen, A; Kim, EJ; Kim, YH; Korman, NJ; Kuzel, TM; Lain, E; Lee, ST; Mangold, AR; Musiek, A; Nikbakht, N; Olsen, E; Pacheco, T; Pariser, D; Piette, W; Poligone, B; Pullion, C; Querfeld, C; Rook, AH; Rumage, A; Schaber, CJ; Seminario-Vidal, L; Shinohara, M; Straube, R; Wong, HK; Wood, GS; Zeitouni, N; Zwerner, JP, 2022) |
| "Hypericin (Hy) is a potent lipid-soluble photosensitiser with promising anticancer therapeutic activities." | 1.72 | Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer. ( Abd-El-Azim, H; Ali, A; Aly, RG; Bell, SJ; Donnelly, RF; Furlong, F; Khalafallah, N; McCarthy, HO; Mcdaid, W; Nafee, N; Rahman, T; Ramadan, A; Tekko, IA; Vora, LK, 2022) |
| "Hypericin was taken up by all melanoma cells and partially co-localized to the endoplasmic reticulum, mitochondria, lysosomes and melanosomes, but not the nucleus." | 1.40 | St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. ( Davids, LM; Kleemann, B; Lang, D; Loos, B; Scriba, TJ, 2014) |
| "Hypericin is a photodynamic compound activated by either visible (400-700 nm) or UVA (320-400 nm) light, and has been shown to inhibit the growth of a variety of neoplastic cell types." | 1.30 | Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. ( Fox, FE; Niu, Z; Rook, AH; Tobia, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abd-El-Azim, H | 1 |
| Tekko, IA | 1 |
| Ali, A | 1 |
| Ramadan, A | 1 |
| Nafee, N | 1 |
| Khalafallah, N | 1 |
| Rahman, T | 1 |
| Mcdaid, W | 1 |
| Aly, RG | 1 |
| Vora, LK | 1 |
| Bell, SJ | 1 |
| Furlong, F | 1 |
| McCarthy, HO | 1 |
| Donnelly, RF | 1 |
| Kim, EJ | 1 |
| Mangold, AR | 1 |
| DeSimone, JA | 1 |
| Wong, HK | 1 |
| Seminario-Vidal, L | 1 |
| Guitart, J | 1 |
| Appel, J | 1 |
| Geskin, L | 1 |
| Lain, E | 1 |
| Korman, NJ | 1 |
| Zeitouni, N | 1 |
| Nikbakht, N | 1 |
| Dawes, K | 1 |
| Akilov, O | 1 |
| Carter, J | 1 |
| Shinohara, M | 1 |
| Kuzel, TM | 1 |
| Piette, W | 1 |
| Bhatia, N | 1 |
| Musiek, A | 1 |
| Pariser, D | 1 |
| Kim, YH | 1 |
| Elston, D | 1 |
| Boh, E | 1 |
| Duvic, M | 2 |
| Huen, A | 1 |
| Pacheco, T | 1 |
| Zwerner, JP | 1 |
| Lee, ST | 1 |
| Girardi, M | 1 |
| Querfeld, C | 1 |
| Bohjanen, K | 1 |
| Olsen, E | 1 |
| Wood, GS | 2 |
| Rumage, A | 1 |
| Donini, O | 1 |
| Haulenbeek, A | 1 |
| Schaber, CJ | 1 |
| Straube, R | 1 |
| Pullion, C | 1 |
| Rook, AH | 3 |
| Poligone, B | 1 |
| Naidoo, C | 1 |
| Kruger, CA | 1 |
| Abrahamse, H | 1 |
| Larisch, P | 1 |
| Verwanger, T | 2 |
| Onder, K | 1 |
| Krammer, B | 2 |
| Noell, S | 1 |
| Feigl, GC | 1 |
| Serifi, D | 1 |
| Mayer, D | 1 |
| Naumann, U | 1 |
| Göbel, W | 1 |
| Ehrhardt, A | 1 |
| Ritz, R | 1 |
| Kleemann, B | 2 |
| Loos, B | 1 |
| Scriba, TJ | 1 |
| Lang, D | 1 |
| Davids, LM | 4 |
| Biteghe, FN | 1 |
| Cooper, S | 1 |
| Kidson, SH | 1 |
| Sanovic, R | 1 |
| Grumboeck, S | 1 |
| Vonderheid, EC | 1 |
| Tobia, A | 2 |
| Cabana, B | 1 |
| Boiy, A | 2 |
| Roelandts, R | 2 |
| de Witte, PA | 3 |
| Sharma, KV | 1 |
| Koren, H | 1 |
| Schenk, GM | 1 |
| Jindra, RH | 1 |
| Alth, G | 1 |
| Ebermann, R | 1 |
| Kubin, A | 1 |
| Koderhold, G | 1 |
| Kreitner, M | 1 |
| Fox, FE | 1 |
| Niu, Z | 1 |
| Martens, A | 1 |
| de Moor, A | 1 |
| Waelkens, E | 1 |
| Merlevede, W | 2 |
| De Witte, P | 2 |
| Delaey, E | 1 |
| Vandenbogaerde, A | 1 |
| Chen, B | 1 |
| Zupkó, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma[NCT02448381] | Phase 3 | 169 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks
| Intervention | lesions with response (Number) |
|---|---|
| SGX301 (Cycle 1 & 2 = SGX301) | 65 |
| Placebo (Cycle 1) | 14 |
"The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks
| Intervention | lesions with response (Number) |
|---|---|
| SGX301 (Cycle 1 & 2 = SGX301) | 64 |
| Placebo (Cycle 1) | 7 |
1 review available for hypericin and Skin Neoplasms
| Article | Year |
|---|---|
Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma.
Topics: Aminolevulinic Acid; Anthracenes; Biopsy, Fine-Needle; Drug Carriers; Early Diagnosis; Humans; Indol | 2019 |
2 trials available for hypericin and Skin Neoplasms
| Article | Year |
|---|---|
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Topics: Adult; Anthracenes; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoide | 2022 |
A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anthracenes; Antineoplastic Agents; Female; Humans | 2010 |
15 other studies available for hypericin and Skin Neoplasms
| Article | Year |
|---|---|
Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer.
Topics: Animals; Anthracenes; Lipids; Mice; Nanocapsules; Perylene; Photochemotherapy; Skin Neoplasms | 2022 |
In vitro analysis of photosensitizer accumulation for assessment of applicability of fluorescence diagnosis of squamous cell carcinoma of epidermolysis bullosa patients.
Topics: Anthracenes; Carcinoma, Squamous Cell; Cell Line, Tumor; Epidermolysis Bullosa; False Positive React | 2013 |
Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model.
Topics: Animals; Anthracenes; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Endoscopy; Glioma; | 2013 |
St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death.
Topics: Anthracenes; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Size; Drug Screening A | 2014 |
A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
Topics: Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Neoplasm Metast | 2017 |
Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy.
Topics: Anthracenes; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Huma | 2009 |
Time-resolved gene expression profiling of human squamous cell carcinoma cells during the apoptosis process induced by photodynamic treatment with hypericin.
Topics: Anthracenes; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Gene Expression Profiling; Gene | 2009 |
Photodynamic therapy using topically applied hypericin: comparative effect with methyl-aminolevulinic acid on UV induced skin tumours.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Anthracenes; Antineoplastic Agents; Disease M | 2011 |
Hypericin-PDT-induced rapid necrotic death in human squamous cell carcinoma cultures after multiple treatment.
Topics: Anthracenes; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Hypericum; Necrosis; Perylene; Phot | 2012 |
Influence of application and formulation factors on the penetration of hypericin in normal mouse skin and UV induced skin tumors.
Topics: Administration, Topical; Animals; Anthracenes; Female; Fluorescence; Mice; Mice, Hairless; Neoplasms | 2007 |
Hypericin in phototherapy.
Topics: Aged; Anthracenes; Humans; Male; Mesothelioma; Neoplasm Recurrence, Local; Perylene; Photochemothera | 1996 |
Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Cells, Cultured; Humans; Keratitis; Lymphocyte Activa | 1998 |
In vitro and in vivo evaluation of hypericin for photodynamic therapy of equine sarcoids.
Topics: Animals; Anthracenes; Cell Line; Equidae; Female; Horse Diseases; Horses; Humans; Perylene; Photoche | 2000 |
Photocytotoxicity of hypericin in normoxic and hypoxic conditions.
Topics: Anthracenes; Cell Hypoxia; Cell Survival; Darkness; Glass; Humans; Light; Neutral Red; Perylene; Pol | 2000 |
Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy.
Topics: Animals; Anthracenes; Blood Vessels; Dose-Response Relationship, Drug; Female; Fluorescein; Hydralaz | 2001 |